John Lee

Apr 17, 2024 | cell.com | John Lee |Trent M Woodruff

The persistence or recurrence of symptoms after acute SARS-CoV-2 infection, termed ‘long COVID’, presents a formidable challenge to global healthcare systems. Recent research by Cervia-Hasler and colleagues delves into the intricate immunological landscape in patients with long COVID, demonstrating an interplay between complement and coagulation, driven by antiviral antibodies and tissue damage.

Apr 12, 2024 | thejns.org | John Lee |Daniel Lee |Jacob Joseph |Jaes C. Jones

Share Link Copy this link, or click below to email it to a friend Email this content or copy the link directly: The link was not copied. Your current browser may not support copying via this button.

Mar 27, 2024 | onlinelibrary.wiley.com | John Lee |Jakob Richter |Martin R. Pfaller |Jason M. Szafron

REFERENCES 1, , , et al. Virtual transcatheter interventions for peripheral pulmonary artery stenosis in Williams and Alagille syndromes. J Am Heart Assoc. 2022; 11(6):e023532. 2, . Interventional catheterization in adult congenital heart disease. Circulation. 2007; 115(12): 1622-1633. 3, . Interventional strategies in the management of peripheral pulmonary artery stenosis. J Interv Cardiol. 2003; 16(2): 171-188. 4, , , . Outcomes of pulmonary artery reconstruction in Williams syndrome.

Jan 29, 2024 | datasciencecentral.com | Ahana Pearl |John Lee

In recent years, the integration of chatbots in healthcare has transcended mere operational assistance, expanding into a realm of innovative solutions for complex challenges. This article explores the versatile applications of healthcare chatbots, shedding light on their transformative impact on patient care and medical processes. Traditionally, renowned platforms like WebMD and Mayo Health provided online symptom checkers, which essentially functioned as AI chatbots.

Aug 1, 2023 | urotoday.com | John Lee

Andrea Miyahira interviews John Lee about his team's publication in Nature Communications. Dr. Lee discusses the focus of their research on a protein called STEAP1, known to be enriched in prostate cancers and the target of substantial therapeutic development. He provides an overview of previous efforts, such as Genentech's discontinued ADC, and ongoing developments like Amgen's AMG 509.